Elevated Interleukin 1β and Interleukin 6 Levels in the Serum of Children With Hyperuricemia

Insights

Interleukin 1β (IL-1β) and IL-6 are elevated in children with hyperuricemia (HUA), indicating their potential role in the condition. These inflammatory markers may be linked to disease activity and clinical outcomes in pediatric HUA.

Area of Science:

  • Pediatric Rheumatology
  • Immunology
  • Biochemistry

Background:

  • Hyperuricemia (HUA) in children is associated with various health risks.
  • The role of specific inflammatory markers like interleukin 1β (IL-1β) and IL-6 in pediatric HUA is not fully understood.
  • Understanding these markers could offer insights into HUA pathogenesis and clinical management.

Purpose of the Study:

  • To investigate serum levels of IL-1β and IL-6 in children diagnosed with HUA.
  • To explore the clinical significance and potential correlations of IL-1β and IL-6 with disease characteristics in pediatric HUA.

Main Methods:

  • A cohort of 71 children with HUA and 71 healthy controls were analyzed.
  • Children with HUA were stratified based on the presence of acute gout-like attacks (Group I: with attacks, Group II: without attacks).
  • Serum IL-1β and IL-6 levels were quantified using enzyme-linked immunosorbent assay (ELISA).

Main Results:

  • Elevated serum levels of IL-1β and IL-6 were observed in children with HUA compared to controls.
  • Significantly higher IL-1β and IL-6 levels were found in acute (IA) and remission (IB) phases of gout attacks, and in children without attacks (II) versus controls.
  • IL-1β and IL-6 positively correlated with markers of inflammation (WBC, neutrophils, ESR, CRP) and kidney function (BUN, creatinine) in HUA patients.

Conclusions:

  • Increased serum IL-1β and IL-6 levels are present in children with HUA, irrespective of acute gout history.
  • These cytokines may reflect underlying inflammation and disease activity in pediatric HUA.
  • Further research is warranted to determine the long-term prognostic significance of IL-1β and IL-6 in this population.
Abstract